Agiliti, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AGTI research report →
Range $20 – $20
Price Chart
About the company
Agiliti, Inc. delivers comprehensive healthcare technology management and service solutions across the United States. Its offerings include robust on-site managed services, which encompass the organization, reprocessing, and logistical coordination of medical equipment directly at client facilities and integrated delivery networks.
- CEO
- Thomas J. Leonard
- IPO
- 2021
- Employees
- 5,800
- HQ
- Eden Prairie, MN, US
Get TickerSpark's AI analysis on AGTI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.37B
- P/E
- -71.79
- Fwd P/E
- 15.91
- PEG
- 0.68
- P/S
- 1.16
- P/B
- 1.44
- EV/EBITDA
- 10.93
- Div Yield
- 0.00%
- Gross Margin
- 34.40%
- Op Margin
- 5.76%
- Net Margin
- -1.65%
- ROE
- -2.06%
- ROIC
- 2.35%
Latest fiscal year · YoY change
- Revenue
- $1.17B+4.8%
- Gross Profit
- $404.10M-6.2%
- Op Income
- $67.69M
- Net Income
- $-19,425,000-164.3%
- EPS
- $-0.14-160.9%
- OCF Growth
- -15.0%
- FCF Growth
- -25.7%
- 52W High
- $18.61
- 52W Low
- $5.07
- 50D MA
- $10.03
- 200D MA
- $8.46
- Beta
- 1.59
- RSI (14)
- 55
- Avg Volume
- 2.77M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Agiliti posted Q3 revenue growth, but margins and EPS fell as mix shifted away from peak-need rental and the company reset its near-term focus toward improving execution and margins.· November 7, 2023
- Q3 revenue was $292 million, up 8% year over year, but adjusted EBITDA fell 7% to $62 million and adjusted EPS declined to $0.09 from $0.19.
- Gross margin rate was 33% versus 37% a year ago, pressured by lower peak-need rental, new clinical engineering customer onboarding, and lower renewal pricing on the HHS agreement.
- Management reaffirmed full-year 2023 guidance: revenue of $1.16 billion to $1.19 billion, adjusted EBITDA of $260 million to $270 million, adjusted EPS of $0.54 to $0.59, and capex of $80 million.
- Tom Leonard returned as CEO and said the company has ‘far more room to execute’ and will focus on rebalancing mix, building local market density, and reducing reliance on third-party service partners.
- Capital allocation is shifting toward debt reduction and reinvestment; M&A is paused and share buybacks are not expected in the foreseeable future.
Q3 2023 revenue was $292 million, up 8% year over year. Adjusted EBITDA was $62 million, down 7% year over year, with adjusted EBITDA margin of 21%. Adjusted EPS was $0.09 versus $0.19 in the prior-year quarter. Gross margin dollars were $97 million, down 5% year over year, and gross margin rate was 33% versus 37% last year. Equipment Solutions revenue was $113 million, up 10%; Clinical Engineering revenue was $115 million, up 11%; and Onsite Managed Services revenue was $64 million, down 1%. For full-year 2023, guidance was reaffirmed for revenue of $1.16 billion to $1.19 billion, adjusted EBITDA of $260 million to $270 million, adjusted EPS of $0.54 to $0.59, and capex of $80 million.
Tom Leonard struck an upbeat but corrective tone, saying Agiliti is ‘under achieving’ relative to its potential and that the business does not face a structural long-term hurdle. He emphasized rebalancing the sales mix, rebuilding local market density, and improving execution across the portfolio rather than relying on a big turnaround or new sales force. He also highlighted growth opportunities in specialty beds/surfaces, surgical services, and clinical engineering, while saying changes should show up over a few quarters rather than immediately.
Jim Pekarek said Q3 revenue rose to $292 million, but adjusted EBITDA fell to $62 million and gross margin rate compressed to 33% from 37%. He attributed the margin pressure to the revised scope of the HHS contract renewal, lower peak-need rental placements, and mix shifts in equipment solutions, partly offset by growth in SES and surgical services. On the balance sheet, he said net debt was $1.05 billion, cash flow from operations for the first nine months was $148 million, leverage was approximately 3.87x, and liquidity was $323 million including $30 million of cash and $293 million available on the revolver; the company is prioritizing debt reduction and ordinary-course reinvestment.
Analysts pressed for 2024 direction, asking about margin expansion, the swing factors for next year, and how quickly the mix shift could take hold. Leonard said margin improvement is driven more by better mix and local market density than by peak-need rental alone, and he described the reset as a series of smaller operational adjustments that should take a few quarters to show up in results. On capital allocation, Pekarek said the company will balance debt paydown and reinvestment, while M&A is paused and buybacks are not expected soon. When asked about hospital cost pressure, management said Agiliti’s value proposition is strongest when customers are under pressure because it can reduce equipment ownership, rental reliance, and repair costs.
Management said Agiliti has multiple organic growth levers already in the business, including SES, surgical services, and clinical engineering, with room to improve profitability through better mix and local market execution. Leonard was optimistic that upcoming product simplification in specialty beds/surfaces and existing competitive positions in surgical services and surgical equipment repair can support margin expansion and growth. They also reaffirmed full-year guidance despite the margin pressure in Q3.
Q3 showed clear margin pressure: gross margin rate fell to 33% from 37%, adjusted EBITDA declined 7%, and adjusted EPS dropped to $0.09 from $0.19. Management said lower peak-need rental, HHS renewal pricing, and onboarding large new customers hurt margins, and Leonard warned that improvement will be gradual over several quarters rather than immediate. The balance sheet remains leveraged at about 3.87x, so the company is prioritizing debt reduction and has paused M&A and share repurchases.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 48.6%
- Shares Outstanding
- 136.08M
- Float Shares
- 66.15M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Credit Suisse AG/ | 66.34K | ▼ 3.18K |
| Oracle Alpha Inc. | 10.72K | ▼ 3.29K |
Held by 2 ETFs
Biggest fund positions in AGTI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 7, 24 | HARRIS C MARTIN | sell | 19,150 |
| May 7, 24 | PATRICK DIANE B. | sell | 36,901 |
| May 7, 24 | FRIEDMAN DARREN M. | sell | 11,800 |
| May 7, 24 | FRIEDMAN DARREN M. | sell | 50,909 |
| May 7, 24 | FRIEDMAN DARREN M. | sell | 55,703 |
| May 7, 24 | Gottlieb Gary L. | sell | 51,344 |
| May 7, 24 | Gottlieb Gary L. | sell | 50,909 |
| May 7, 24 | Workman John L | sell | 39,401 |
| May 7, 24 | Workman John L | sell | 27,653 |
| May 7, 24 | Workman John L | sell | 55,703 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AGTI coverage
Recent articles, reports, and earnings notes.
No research on AGTI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AGTI report →Agiliti Named Exclusive U.S. Provider of Total Lift Bed, Addressing Growing Challenges in Critical Care through Advanced Early Mobility Solutions
businesswire.com · Jun 16
Agiliti Introduces Capillaire™ — Low-Profile Alternating Pressure Overlay Clinically Proven to Prevent Perioperative Pressure Injuries
businesswire.com · Apr 7
Agiliti Expands Oncology Offerings with Innovative Prostate Cancer Technologies and Services
businesswire.com · Sep 23
Agiliti Introduces New Line of Stretcher Support Surfaces
businesswire.com · Jun 9
Agiliti to Premiere Essentia Bed Frame and Adapt Line Surfaces at the American Organization of Nursing Leadership Conference
businesswire.com · Mar 25
Agiliti Launches Essentia™, an Innovative Multi-Acuity Hospital Bed that Helps Lower Patient Risk and Accelerate Mobility
businesswire.com · Feb 11
Lowey Dannenberg, P.C. is Investigating the Proposed Acquisition of Agiliti, Inc. (NYSE: AGTI) by Private Equity Firm Thomas H.
globenewswire.com · Jun 24
Lowey Dannenberg, P.C. is Investigating the Proposed Acquisition of Agiliti, Inc. (NYSE: AGTI) by Private Equity Firm Thomas H.
globenewswire.com · Jun 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.